Comparative Pharmacology
Head-to-head clinical analysis: OBREDON versus TENORETIC 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OBREDON versus TENORETIC 50.
OBREDON vs TENORETIC 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clonidine is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, leading to decreased peripheral vascular resistance and blood pressure.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume.
Adults: 10 mg orally once daily. For patients requiring more rapid relief, initial dose of 20 mg once daily may be used; switch to 10 mg once daily after 4 to 8 weeks.
1 tablet (atenolol 50 mg / chlorthalidone 25 mg) orally once daily, may increase to 2 tablets once daily if needed.
None Documented
None Documented
Terminal elimination half-life of 30 hours (range 24-36 hours), supporting once-daily dosing in chronic therapy.
Atenolol: 6-7 hr (up to 20 hr in renal impairment); chlorthalidone: 40-60 hr (prolonged in renal impairment)
Approximately 75% renal excretion as unchanged drug and metabolites, with 25% fecal elimination via biliary secretion.
Renal: atenolol 40-50% unchanged, chlorthalidone >95% unchanged; biliary/fecal minimal
Category C
Category C
Beta blocker/alpha blocker
Beta blocker/thiazide diuretic combination